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Christopher McGuigan[a]
In memory of Prof. Christopher McGuigan
1. Introduction
The C-nucleosides represent a group of nucleoside analogues
in which the sugar moiety is linked to the nucleobase by
a carbon–carbon bond.[1] Several C-nucleosides are naturally
occurring compounds. Among them, pseudouridine was the
first to be isolated from yeast tRNA in 1957.[2] Subsequently,
other C-nucleosides, including oxazinomycin,[3] pyrazomycin,[3]
showdomycin,[4] and formycin A,[5] were isolated from culture
filtrates of different bacterial strains. These compounds are an-
tibiotics and exhibit anti-cancer and/or antiviral activity. Their
advantageous properties arise from the presence of a CC gly-
cosidic bond, which gives a greater resistance than N-nucleo-
sides towards chemical hydrolysis and enzymatic hydrolysis by
phosphorylase and deaminase enzymes. On the basis of these
interesting chemical and biological properties, a wide variety
of synthetic analogues have been prepared thanks to the large
array of novel synthetic methodologies developed in the last
two decades. Several of these compounds have found numer-
ous applications in medicinal chemistry and chemical biology.[1]
Among them, pseudoisocytidine (PIC, 1), a nucleoside isostere
of cytidine was developed as a candidate for anti-leukaemic
therapy[6] (Figure 1). PIC was shown to be incorporated into
both RNA and DNA and this incorporation was considered to
be responsible for its therapeutic activity, which has been ob-
served against several mouse leukaemias in vitro and
in vivo.[7, 8] In addition, PIC was found to disrupt DNA methyla-
tion by inhibition of the enzyme DNA methyltransferase, most
probably due to the presence of a nitrogen atom in the 5-posi-
tion of the base.[9] However, the development of PIC was
halted due to hepatotoxicity observed during phase I clinical
evaluation.[10] The efficiency with which PIC is incorporated
into RNA, and the rapid RNA turnover, associated with protein
synthesis in the liver, were considered the main causes of its
hepatotoxicity. This finding prompted the investigation of 2’-
deoxypseudoisocytidine (2’d-PIC, 2),[11] which, in preliminary
tissue culture experiments, was found to exhibit inhibitory ac-
tivity against P815 cell lines.[11a] PIC, 2’d-PIC and their analogues
were also used as novel base-pairing agents in oligonucleo-
tides to investigate DNA and RNA structures and functions.[12]
Although several C-nucleoside analogues have been described
as anti-cancer and/or antiviral agents, none have ever been de-
veloped as anti-cancer or antiviral drugs. The recent advent of
two novel C-nucleosides, BCX4430 (3)[13] and GS-6620 (4),[14] as
potential therapeutic agents for the treatment of the Ebola
virus and hepatitis C virus (HCV) infections, respectively, has
stimulated renewed interest in this class of compounds
(Figure 1).
As part of our current research we were interested to further
investigate the potential utility of 2’d-PIC (2) as an anti-leukae-
mic agent by preparing a series of phosphoramidate prodrugs
for biological evaluation as anti-cancer agents. “ProTides” in
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the clinic have consistently showed greater efficacy and more
favourable safety profiles relative to the corresponding stan-
dard-of-care nucleoside analogues. Several pharmaceutical
companies have already validated the phosphoramidate ap-
proach for antiviral applications. In 2014, Gilead launched on
the market its anti-HCV ProTide, sofosbuvir (5)[15] and in the fol-
lowing year tenofovir alafenamide (TAF, 6),[16] an anti-HIV Pro-
Tide (Figure 1). NuCana introduced the ProTide technology to
clinical oncology with NUC-1031 (7),[17] a ProTide of gemcita-
bine, and NUC-3373 (8),[18] a ProTide of 2’-deoxy-5-fluorouri-
dine, currently in phase III and phase I clinical studies, respec-
tively, for patients with advanced solid tumours (Figure 1).
2. Results and Discussion
2.1. Synthesis of 2’-Deoxypseudoisocytidine (2)
Several approaches have been developed for the preparation
of C-glycosides[19] and C-nucleosides.[20] Among them, for the
synthesis of 2’d-PIC (2), we selected the methodology devel-
oped by Daves et al. , which utilises a Pd-catalysed Heck-type
coupling of aryl halides to cyclic enol ethers, either pyranoid or
furanoid glycals.[21] As outlined in Scheme 1, the protected fur-
anoid glycal 12 and the halogenated N-acetyl pseudoisocyto-
sine 11, served as starting materials for the Heck reaction. 2-N-
Acetyl-5-iodoisocytosine (11) was synthesised in good yield in
two steps from commercially available isocytosine (9), which
was first iodinated with N-iodosuccinimide in acetic acid to
afford the intermediate compound 10. Subsequent acetylation
Figure 1. Structures of pseudoisocytidine (PIC, 1), 2’-deoxypseudoisocytidine (2’d-PIC, 2), BCX4430 (3), GS-6620 (4), sofosbuvir (5), tenofovir alafenamide (TAF,
6), NUC-1031 (7), and NUC-3373 (8).
Scheme 1. Synthesis of 2’d-PIC (2). NIS, N-iodosuccinimide; BSA, Bis(trimethylsilyl)acetamide ; DIPEA, N,N-diisopropylethylamine.
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of the exocyclic amino function of 10 using acetic anhydride
yielded the desired nucleobase 11.[22] Compound 12 was pre-
pared from 3’,5’-bis-O-(tert-butyldimethylsilyl)thymidine[23] by
using typical silylation conditions first reported by Pedersen
et al.[24] and then applied by Hammer et al.[25] for the
preparation of furanose glycals with a wide range of O-silyl
protections.
The coupling reaction of 5-iodo base 11 with the protected
ribofuranosyl glycal 12 using Pd(OAc)2 as a catalyst, AsPh3 as
a soft ligand and N,N-diisopropylethylamine as a base, formed
selectively the b-C-nucleoside 13. After removal of the silyl
groups with fluoride ions, the resulting 2’-deoxy-3’-keto C-nu-
cleoside 14 was treated with sodium triacetoxyborohydride to
reduce diastereoselectively the 3’-keto group from the b-face
of the furanosyl ring, forming N-acetyl-2’-deoxypseudoisocyti-
dine 15.[22] The cleavage of the acetyl group to afford nucleo-
side 2 was then accomplished by basic hydrolysis using NH3 in
MeOH. The assignment of the configuration at the 1’-position
of 2 was based on the comparison of its 1H NMR spectrum
with that reported in the literature.[22]
2.2. Synthesis of N-Acetyl-2’-deoxypseudoisocytidine
Phosphoramidates
The two synthetic strategies commonly used for the prepara-
tion of phosphoramidate prodrugs (phosphorochloridate in
the presence of either tert-butylmagnesium chloride or N-
methylimidazole as a base)[26] failed when applied to 2, proba-
bly due to the low solubility of the starting material in the re-
action medium, returning only unreacted starting materials. At-
tempts to improve the solubility of 2 using different solvents
were unsuccessful. Application of the ProTide approach to pre-
cursors 14 and 15 also failed, indicating that development of
a suitable synthetic strategy to afford phosphoramidates
of 2 was more challenging than originally expected. These re-
sults prompted us to use a different synthetic methodology
with compound 17 as the key intermediate (Scheme 2).
We envisaged that introduction of a tert-butyldimethylsilyl
ether at the 3’-OH group in 15 would help to improve its solu-
bility and to achieve exclusive phosphorylation at the 5’-posi-
tion.
In order to prepare compound 17, the two hydroxy groups
of deoxyribose present in N-acetyl-2’-deoxypseudoisocytidine
(15) were first protected with a tert-butyldimethylsilyl group
using tert-butyldimethylsilyl chloride in DMF for 24 h at room
temperature in the presence of 4-dimethylaminopyridine
(DMAP) to provide, after flash chromatography, compound 16
in reasonable yield. Then, selective silyl group deprotection
was achieved with aqueous trifluoroacetic acid to give, after
isolation by silica gel chromatography, 17 with a free primary
hydroxy group in moderate yield. Next, phosphorochloridates
18a–f, prepared as a mixture of RP and SP diastereoisomers ac-
cording to a literature procedure,[26] were reacted with 17 in
the presence of tert-butylmagnesium chloride (1.0m in THF),
yielding 3’-O-tert-butyldimethylsilyl phosphoramidates 20a–f
(Scheme 2) as diastereoisomeric mixtures after column chroma-
tography, except for 20d, which was isolated after purification
as a single diastereoisomer. Despite the almost complete con-
sumption of the starting material, the desired products 20a–f
were recovered in low yields, which was ascribed in each case
to the formation of a bisphosphorylated by-product, as exem-
plified in Figure 2. The bisphosphorylated compound 19 f was
isolated and its structure was characterised by mass spectrom-
etry and 31P and 1H NMR analysis,[31] which clearly suggested
that the phosphorylation involved the oxygen atom of the pyr-
imidine ring rather than either one of the nitrogen atoms. N-
Acetylisocytidine possesses an enolisable keto group which,
like the 5’-OH group, is able to react with a phosphorochlori-
date to give an O-phosphorylated derivative. In support of this
result, we found in the literature that the reaction of 2-acetyla-
mino-4-hydroxypyrimidines with phosphorochloridates gives
O-phosphoryl rather than N-phosphoryl derivatives.[27] The sub-
stantial steric requirement of the phosphoryl chloride and the
steric hindrance exerted to some extent by the acetyl group
Scheme 2. Synthesis of ProTides 21a–f. TBDMSCl, tert-butyldimethylsilyl chloride; DMAP, 4-dimethylaminopyridine; TFA, trifluoroacetic acid.
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were considered to be the key features for preventing phos-
phorylation at either one of the ring nitrogen atoms.[27]
Acidic deprotection of 20a–f afforded after preparative
HPLC purification compounds 21a–f in moderate yields
(Scheme 2 and Table 1). Attempts to remove the acetyl protec-
tion from 21a with Schwartz’s reagent as described by Ferrari
et al. ,[28] failed due to the ring opening of the base. The diffi-
culties encountered in removing the N-acetyl group from 21a–
f using mild conditions, and the fact that the labile PO bond
of the ProTide would not tolerate other harsh de-acetylating
agents such as methanolic ammonia, prompted us to abandon
our attempts toward modification of 21a–f. We therefore con-
tinued our effort to conceive a more efficient route that would
allow the preparation of the N-deacetylated analogues.
2.3. Synthesis of 2’-Deoxypseudoisocytidine
Phosphoramidates
As shown in Scheme 3, compound 22, obtained by treatment
of 16 with methanolic ammonia, underwent selective 5’-desily-
lation using aqueous trifluoroacetic acid in THF to afford the
monosilyl compound 23 in excellent yield. Next, phosphoro-
chloridates 18a and 18g were reacted with 23 in the presence
of tert-butylmagnesium chloride (1.0m in THF) to yield, after
column chromatography, the 3’-O-tert-butyldimethylsilyl-pro-
tected phosphoramidates 24a and 24g in moderate yield as
diastereoisomeric mixtures (Table 2). No traces of bisphos-
phorylated products either due to O- or N-phosphorylation
were observed.
Acidic deprotection of the tert-butyldimethylsilyl moieties in
24a and 24g with trifluoroacetic acid in dichloromethane (1:2
v/v; room temperature, overnight), afforded the final com-
pounds 25a and 25g as mixtures of a and b isomers in a 3:1
ratio after column chromatography. The b-isomers of 25a and
Figure 2. Proposed rationale for the O-phosphorylation side reaction.
Table 1. Reaction outcomes for the synthesis of precursors 20a–f and
ProTides 21a–f.
Cmpd Ar R Yield
[%]
d.r. Cmpd Yield
[%]
d.r.
20a Ph CH2Ph 25 1.5:1 21a 50 2.3:1
20b Ph (CH2)5CH3 21 1.5:1 21b 60 1.5:1
20c Ph (CH2)4CH3 28 1:1 21c 16 1:1
20d Naph CH(CH3)2 12 1:0 21d 37 1:0
20e Naph CH2C(CH3)3 13 1:1 21e 46 2.3:1
20 f Naph CH2Ph 59 1.5:1 21 f 25 4:1
Scheme 3. Synthesis of ProTides 25a and 25g.
Table 2. Reaction outcomes for the synthesis of 24a and 24g and Pro-
Tides 25a and 25g after HPLC purification.
Cmpd Ar R d.r. Yield
[%]
Cmpd Yield
[%]
d.r.
24a Ph CH2Ph 2.3:1 41 25a 62 1:0
24g Ph CH(CH3)2 1:3 32 25g 50 4:1
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25g were isolated in low yield after preparative HPLC purifica-
tion (25a as a single diastereoisomer and 25g as a mixture;
Scheme 3 and Table 2). Most probably, the presence of a disso-
ciable proton on N-1 facilitates the a,b-epimerisation in acidic
conditions through a ring opening–closure of the carbohydrate
ring (Scheme 4) as previously reported for other C--
nucleosides.[11b, c, 29]
If a mild procedure for the cleavage of tert-butyldimethylsilyl
ethers to alcohols (based on an exchange reaction with tri-
methylsilyl triflate at 78 8C)[30] was used, no epimerisation was
observed.
2.4. Enzymatic Studies on the Activation of C-Nucleoside
ProTides
To exert their biological activity, ProTides must be metabolised
in vivo into the monophosphate form, which in turn generates
the active triphosphate form by two consecutive phosphoryla-
tion reactions.[31] In the process of intracellular activation of
ProTides, the first step is catalysed by a carboxyesterase-type
enzyme, such as cathepsin A, which was shown to be responsi-
ble for the cleavage of the amino acid ester moiety.[32] In order
to demonstrate that the ProTides of C-nucleosides are activat-
ed in a similar manner, the interaction of compound 21e with
a carboxyesterase-type enzyme was investigated. Carboxypep-
tidase Y was used as a surrogate of cathepsin A because it be-
longs to the same family of C-type carboxypeptidases and it
was reported to share similarities in the active site.[33]
Compound 21e in [D6]acetone was therefore incubated in
an NMR tube with carboxypeptidase Y in Trizma buffer
(pH 7.6), and the progress of the reaction was monitored by
31P NMR analysis over 14 h. The stacked spectra (Figure 3)
show the formation of a new peak after 10 min of incubation,
which corresponds to intermediate I (dP=5.06 ppm, t=
10 min). Complete conversion of the ProTide 21e (which in
[D6]acetone appears as a single peak at dP=4.26 ppm) into the
corresponding aminoacyl phosphoramidate ester (II : dP=
7.19 ppm) was observed in 40 min. In vivo, the aminoacyl
phosphoramidate ester metabolite is then believed to undergo
PN bond cleavage, mediated by a phosphoramidase-type
enzyme to eventually release the parent drug in its monophos-
phate form.
3. Conclusions
An alternative route to C-nucleoside ProTides has been devel-
oped and used to prepare phosphoramidate derivatives of 2’d-
PIC (2) and N-acetyl 2’d-PIC (15). Unexpected side reactions
such as phosphorylation of the enolisable keto group of the
nucleobase and epimerisation through ring opening highlight-
ed the different reactivity of C-nucleosides compared to nu-
cleoside analogues. The first carboxypeptidase-mediated bioac-
tivation step for this new class of prodrugs followed the same
pathway and rate as reported for ProTides of conventional nu-
cleoside analogues. Biological evaluation of these novel nu-
cleoside analogues should enhance our understanding of the
potential of C-nucleosides as anti-tumour agents and in partic-
ular of 2’d-PIC as an anti-leukaemic drug. Together with deriva-
tives 25a and 25g, we plan to evaluate the N-acetylated deriv-
atives 21a–f for their anti-tumour activity. We considered that
the acetyl moiety would further enhance the lipophilicity of
these compounds and remove the potential for their protona-
tion in vitro, whereas in vivo the acetyl moiety would most
probably be able to undergo cleavage (thus acting as a dual
prodrug). The results of these investigations will be disclosed
in due course.
Experimental Section
Chemistry
All anhydrous solvents were purchased from Sigma–Aldrich and
amino acid esters from Novabiochem. All commercially available
reagents were used without further purification.
Scheme 4. Proposed mechanism for the epimerisation of C-nucleoside phos-
phoramidates under acidic conditions.
Figure 3. Deconvoluted 31P NMR spectra (202 MHz, [D6]acetone/pH 7.6
Trizma buffer) to show the carboxypeptidase-mediated activation of com-
pound 21e.
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Precoated aluminium-backed plates (60F254, 0.2 mm thickness,
Merck) were used for thin-layer chromatography (TLC) and were vi-
sualised under both short- and long-wavelength UV light (254 and
366 nm, respectively). Flash column chromatography was per-
formed using silica gel supplied by Fisher (60A, 35–70 mm). Analyti-
cal HPLC analysis was performed using either a ThermoScientific or
a Varian Prostar system. 1H (500 MHz), 13C (125 MHz), and 31P NMR
(202 MHz) spectra were recorded on a Bruker Avance 500 MHz
spectrometer at 25 8C. Chemical shifts (d) are quoted in parts per
million (ppm) relative to internal references CD3OD (d=3.34 ppm,
1H NMR; d=49.86 ppm, 13C NMR) and CDCl3 (d=7.26 ppm,
1H NMR; d=77.4 ppm, 13C NMR), or external 85% H3PO4 (d=
0.00 ppm, 31P NMR). Coupling constants (J) are expressed in Hertz.
The following abbreviations are used in the assignment of NMR
signals: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet),
br s (broad singlet), dd (doublet of doublet), dt (doublet of triplet).
Low-resolution mass spectrometry was performed on a Bruker Dal-
tonics micrOTOF–LC system.
For practical purposes, in some cases standard procedures are
given. Procedures that differ from the standard are fully described.
N-(6-Oxo-1,6-dihydropyrimidin-2-yl)acetamide (10)
N-Iodosuccinimide (22.0 g, 98 mmol) was added to a solution of 2-
aminopyrimidin-4(3H)-one (9, 10.0 g, 90 mmol) in acetic acid
(170 mL) at 70 8C. The resulting suspension was heated at 100 8C
and stirred for 1 h. The reaction mixture was cooled to room tem-
perature and H2O (500 mL) was added. The solid was filtered,
washed with H2O and dried with a heat gun at 50 8C for 12 h to
afford compound 10 as a light pink solid (12.8 g, 60% yield).
1H NMR (500 MHz, DMSO): d=11.24 (br s; NH), 7.93 (s, 1H; H-6),
6.69 ppm (s, 2H; NH2).
N-(5-Iodo-6-oxo-1,6-dihydropyrimidin-2-yl)acetamide (11)
A suspension of 10 (11.8 g, 49.8 mmol) and acetic anhydride
(11.8 mL, 124.5 mmol) in DMF (200 mL) was heated to 100 8C. After
1.5 h the clear solution was evaporated to dryness under high
vacuum and the residue was suspended in EtOH. The solid was fil-
tered off and washed with Et2O to afford 11 as a white solid (9.2 g,
66% yield). 1H NMR (500 MHz, DMSO): d=12.15 (s, 1H; NH), 11.74
(br s; NH), 8.31 (s, 1H; H-6), 2.16 ppm (s, 3H; CH3) ;
13C NMR
(125 MHz, DMSO): d=173.5 (C=O), 166.4 (C-4), 152.2 (C-2), 150.8
(C-6), 81.3 (C-5), 23.0 ppm (COCH3).
N-(5-{(2’R,5’R)-4’-[(tert-Butyldimethylsilyl)oxy]-5’-{[(tert-butyldi-
methylsilyl)oxy]methyl}-2’,5’-dihydrofuran-2-yl}-6-oxo-1,6-dihy-
dropyrimidin-2-yl)acetamide (13)
N,O-Bis(trimethylsilyl)-acetamide (9 mL, 7.5 g, 37 mmol) was added
dropwise to a suspension of 11 (8.0 g, 29 mmol) in DMF (50 mL)
under an argon atmosphere. After stirring for 1 h the reaction
become a clear solution. Then N,N-diisopropylethylamine (6.3 mL,
4.67 g, 36 mmol) and 1,4-anhydro-3,5-O-bis(tert-butyldimethylsilyl)-
2-deoxy-d-erythro-pent-1-enitol (12, 4.0 g, 11.6 mmol) were added.
In a separate flask, Pd(OAc)2 (0.5 g, 2.2 mmol) was added to a solu-
tion of triphenylarsine (1.3 g, 4.2 mmol) in stirring DMF (100 mL).
After 30 min, this solution was added slowly to the first flask and
the mixture was stirred for 24 h at 80 8C. The reaction was
quenched with the addition of H2O (30 mL) and the solvent was
evaporated under reduced pressure. The residue was redissolved
in EtOAc (500 mL), and washed with H2O (2200 mL) and brine
(200 mL). The organic layer was dried over MgSO4, filtered and con-
centrated under reduced pressure. The residue was purified by
column chromatography on silica gel (EtOAc/hexane 7:3) to give
13 as a light yellow solid (2.8 g, 52% yield). 1H NMR (500 MHz,
CDCl3): d=12.30 (br s, 1H; NH), 9.86 (br s, 1H; NH), 8.04 (s, 1H; H-
6), 5.75 (s, 1H; H-1’), 4.92 (s, 1H; H-2’), 4.53–4.51 (m, 1H; H-4’), 3.84
(dd, J=11.5, 2.5 Hz, 1H; H-5’a), 3.69 (dd, J=11.5, 4.0 Hz, 1H; H-5’b),
0.92 (s, 9H; C(CH3)3), 0.90 (s, 9H; C(CH3)3), 0.09 (s, 6H; Si(CH3)2),
0.02 ppm (s, 6H; Si(CH3)2) ;
13C NMR (125 MHz, CD3OD): d=174.2
(C=O), 161.3 (C-4), 151.4 (C-6), 148.1 (C-2), 123.0 (C-5), 101.3 (C-2’),
85.4 (C-4’), 77.9 (C-1’) 64.7 (C-5’), 26.5 (SiC(CH3)3), 26.1 (SiC(CH3)3),
22.5 (COCH3), 19.4 (SiC(CH3)3), 18.8 (SiC(CH3)3), 6.1 (Si(CH3)2),
6.3 ppm (Si(CH3)2) ; MS (ES
+): m/z (%): 496 [M+H]+ (40), 518.26
[M+Na]+ (100).
N-{5-[(2’R,4’S,5’R)-4’-Hydroxy-5’-(hydroxymethyl)tetrahydrofur-
an-2’-yl]-6-oxo-1,6-dihydropyrimidin-2-yl}acetamide (15)
70% HF–pyridine (2.9 mL) was added dropwise to a solution of 13
(3.0 g, 6.0 mmol) in THF (100 mL). The reaction was stirred at room
temperature for 12 h under an argon atmosphere. The suspension
was diluted with acetic acid (30 mL) and the volatiles removed
under reduced pressure to obtain crude compound 14, which was
used in the next step without further purification. 1H NMR
(500 MHz, CD3OD): d=8.1 (s, 1H; H-6), 5.17 (dd J=10.2, 6.8 Hz 1H;
H-1’), 4.04 (t, J=3.5 Hz, 1H; H-4’), 3.65 (dd, J=12.2, 2.6 Hz, 1H; H-
5’a), 3.61 (dd, J=12.2, 3.5 Hz, 1H; H-5’b), 2.89–2.86 (m, 1H; H-2’a),
2.53–2.50 (m, 1H; H-2’b), 2.23 ppm (s, 3H; CH3) ; MS (ESI, negative-
ion mode): m/z : found 266.20 [MH]+ 100%; reversed-phase
HPLC, eluting with H2O/CH3CN from 98/2 to 0/100 in 45 min,
flow=1 mLmin1, l=254 nm, tR=7.75 min.
The residue was dissolved in a mixture of acetic acid/CH3CN (1:1
v/v, 200 mL) and the mixture was cooled to 15 8C, followed by
the portionwise addition of NaBH(OAc)3 (3.0 g, 14.1 mmol). After
2 h, the mixture was evaporated to dryness under reduced pres-
sure and the residue was purified by flash column chromatography
(CH2Cl2/CH3OH 8:2) to give 15 as a white solid (1.3 g, 80% yield).
1H NMR (500 MHz, [D6]DMSO): d=12.09 (br s, 1H; NH), 11.73 (br s,
1H; NH), 8.1 (s, 1H; H-6), 5.14 (br s, 1H; 5’-OH), 4.95–4.90 (m, 1H;
H-1’), 4.09 (t, J=3.3 Hz, 1H; H-4’), 3.65 (ddd, J=12.0, 4.2, 2.5 Hz,
1H; H-5’a), 3.61 (ddd, J=12.5, 7.3, 2.5 Hz, 1H; H-5’b), 3.17 (d, J=
5.4 Hz, 1H; 3’-OH), 2.76 (dd, J=17.6, 6.6 Hz, 1H; H-2’a), 2.42 (dd,
J=17.5, 10.0 Hz, 1H; H-2’b), 2.16 ppm (s, 3H; CH3) ;
13C NMR
(125 MHz, CD3OD): d=175.1 (C=O), 159.6 (C-4), 153.6 (C-6), 152.7
(C-2), 123.4 (C-5), 88.9 (C-4’), 75.7 (C-1’), 73.4 (C-3’), 64.1 (C-5’), 41.7
(C-2’), 23.9 ppm (CH3) ; MS (ES
+): m/z (%): calcd for C11H15N3O5 : 269
[M] ; found: 291.09 [M+Na]+ (100); reversed-phase HPLC, eluting
with H2O/CH3OH from 90:10 to 0:100 in 30 min, flow=1 mLmin
1,
l=254 nm, tR=4.87 min.
2-Amino-5-[(2’R,4’S,5’R)-4’-hydroxy-5’-(hydroxymethyl)tetrahy-
drofuran-2’-yl]pyrimidin-4(3H)-one (2)
Ammonia in MeOH (7m, 1 mL) was added to a stirred solution of
15 (20.0 mg, 0.074 mmol) in MeOH (0.2 mL) at 0 8C under an argon
atmosphere. After 30 min, the mixture was allowed to reach room
temperature and was stirred for a further 6 h. The volatiles were re-
moved under reduced pressure and the crude material was puri-
fied by preparative reversed-phase HPLC (eluting with H2O/CH3OH
from 100/0 to 0/100 over 30 min, flow rate 20 mLmin1) to give 2
as a white solid (12.0 mg, 71% yield). 1H NMR (500 MHz, CD3OD):
d=7.68 (s, 1H; H-6), 5.00 (s, 1H; H-1’), 4.33 (d J=5.6 Hz, 1H; H-3’),
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3.94–3.92 (m, 1H; H-4’), 3.83 (dd, J=12.2, 3.6 Hz, 1H; H-5’a), 3.63
(dd, J=12.7, 4.0 Hz, 1H; H-5’b), 2.23–2.17 (m, 1H; H-2’a), 2.10 ppm
(dd, J=13.0, 6.0 Hz, 1H; H-2’b); 13C NMR (125 MHz, CD3OD): d=
166.1 (C-4), 156.3 (C-2), 148.6 (C-6), 114.6 (C-5), 87.5 (C-4’), 76.0 (C-
1’), 73.4 (C-3’), 62.6 (C-5’), 40.3 ppm (C-2’) ; MS (ES+): m/z (%):
228.04 [M+H]+ (50), 250.01 [M+Na]+ (100); reversed-phase HPLC,
eluting with H2O/CH3OH from 90:10 to 0:100 in 30 min, flow=
1 mLmin1, l=254 nm, tR=4.57 min.
N-[5-((2’R,4’S,5’R)-4’-[(tert-Butyldimethylsilyl)oxy]-5’-{[(tert-bu-
tyldimethylsilyl)oxy]methyl}tetrahydrofuran-2’-yl)-6-oxo-1,6-di-
hydropyrimidin-2-yl]acetamide (16)
Imidazole (0.4 g, 5.8 mmol), tert-butyldimethylsilyl chloride (0.44 g,
2.9 mmol) and DMAP (0.04 g, 0.33 mmol) were added to a solution
of 15 (0.34 g, 1.26 mmol) in DMF (2.5 mL) at room temperature
under an argon atmosphere and the reaction was stirred at room
temperature for 24 h. The reaction mixture was then quenched
with CH3OH (1 mL) and the solvent was removed under reduced
pressure. The residue was diluted with CH2Cl2 (5 mL) and washed
with H2O (2 mL), NaHCO3 (2 mL) and brine (2 mL). The organic
layer was dried over MgSO4, filtered and concentrated under re-
duced pressure. The crude product was purified by flash column
chromatography (EtOAc/hexane 7:3) to give 16 as a white solid
(0.410 g, 65% yield). 1H NMR (500 MHz, CD3OD): d=7.85 (s, 1H; H-
6), 4.98 (dd, J=9.0, 5.5 Hz, 1H; H-1’), 4.32–4.30 (m, 1H; H-3’), 3.78–
3.76 (m, 1H; H-4’), 3.64 (dd, J=10.5, 4.5 Hz, 1H; H-5’a), 3.56 (dd,
J=10.5, 4.5 Hz, 1H; H-5’b), 2.21–2.16 (m, 1H; H-2’a), 2.10 (s, 3H;
CH3), 1.79–1.69 (m, 1H; H-2’b), 0.83 (s, 9H; C(CH3)3), 0.81 (s, 9H;
C(CH3)3), 0.02 (s, 3H; Si(CH3)2), 0.02 (s, 3H; Si(CH3)2), 0.01 (s, 3H;
Si(CH3)2), 0.00 ppm (s, 3H; Si(CH3)2) ;
13C NMR (125 MHz, CD3OD):
d=173.6 (C=O), 159.6 (C-4), 151.0 (C-6), 148.4 (C-2), 123.1 (C-5),
87.6 (C-4’), 74.1 (C-1’, C-3’), 63.4 (C-5’), 40.9 (C-2’), 25.1 (C(CH3)3),
25.0 (C(CH3)3), 22.5 (COCH3), 17.8 (C(CH3)3), 17.5 (C(CH3)3), 5.8
(Si(CH3)2), 5.9 (Si(CH3)2), 6.6 (Si(CH3)2), 6.7 ppm (Si(CH3)2) ; MS
(ES+): m/z (%): 498.3 [M+H]+ (50), 519.2 [M+Na]+ (100).
N-(5-{(2’R,4’S,5’R)-4’-[(tert-Butyldimethylsilyl)oxy]-5’-(hydroxy-
methyl)tetrahydrofuran-2’-yl}-6-oxo-1,6-dihydropyrimidin-2-
yl)acetamide (17)
A mixture of TFA and H2O (1:1 v/v, 2.4 mL) was added dropwise to
a solution of 16 (0.3 g, 0.6 mmol) in THF (4.8 mL) at 0 8C. The reac-
tion mixture was stirred at room temperature for 2 h under an
argon atmosphere, then quenched with aqueous NaHCO3 ; CH2Cl2
was added and the aqueous phase was extracted twice with
CH2Cl2. The combined organic layers were dried over MgSO4, fil-
tered and concentrated under vacuum to yield 17 as a glassy solid
(0.172 g, 75%), which was used in the next step without further
purification. 1H NMR (500 MHz, CD3OD): d=7.92 (s, 1H; H-6), 4.94
(dd, J=9.0, 5.5 Hz, 1H; H-1’), 4.45–4.42 (m, 1H; H-3’), 3.75 (dt, J=
4.5, 2.5 Hz, 1H; H-4’), 3.68 (dd, J=11.9, 4.5 Hz, 1H; CH2a-5’), 3.66
(dd, J=11.9, 4.5 Hz, 1H; CH2b-5’), 2.30–2.14 (m, 1H; CH2a-2’), 2.22 (s,
3H; CH3), 2.12–1.99 (m, 1H; CH2b-2’), 0.95 (s, 9H; C(CH3)3), 0.02 (s,
3H; Si(CH3)2), 0.01 ppm (s, 3H; Si(CH3)2) ;
13C NMR (125 MHz,
CD3OD): d=173.5 (C=O), 160.3 (C-4), 149.9 (C-6), 148.2 (C-2), 123.0
(C-5), 87.5 (C-4’), 83.7 (C-1’), 74.2 (C-3’), 71.0 (C-5’), 39.4 (C-2’), 25.0
(SiC(CH3)3), 22.5 (COCH3), 17.7 (SiC(CH3)3), 5.9 (Si(CH3)2), 6.6 ppm
(Si(CH3)2) ; MS (ES
+): m/z (%): 384.2 [M+Na]+ (100); reversed-phase
HPLC, eluting with H2O/CH3OH from 90:10 to 0:100 in 30 min,
flow=1 mLmin1, l=254 nm, tR=16.37 min.
Standard Procedure 1: Synthesis of Phosphorochloridates
18a–g
Anhydrous triethylamine (2.0 mol equiv.) was added dropwise at
78 8C to a stirred solution of the appropriate amino ester hydro-
chloride/tosylate salt (1.0 mol equiv.) and the appropriate dichloro-
phosphate (1.0 mol equiv.) in anhydrous dichloromethane
(61.6 mol) under an argon atmosphere. After 1 h the reaction mix-
ture was allowed to warm to room temperature and was stirred
for an additional 1–2 h. Formation of the desired phosphorochlori-
date was monitored by 31P NMR spectroscopy. After the reaction
was completed, the solvent was removed under reduced pressure
and the resulting residue was re-dissolved in anhydrous diethyl
ether and the triethylammonium salt was removed by filtration.
The filtrate was evaporated to dryness and the crude material was
purified by flash column chromatography with ethyl acetate/
hexane (1:1 v/v) as the eluent to give the desired phosphorochlori-
date as an oil.
Phenyl-(benzoxy-l-alaninyl)-phosphorochloridate (18a)
Prepared according to standard procedure 1 in 92% yield. 1H NMR
(500 MHz, CDCl3): d=7.30–7.10 (m, 10H; H-Ar), 5.20–5.16 (m, 2H;
OCH2Ph), 4.25–4.22 (m, 1H; CHCH3), 3.51–3.48 (m, 1H; NH), 1.54 (d,
J=7.3 Hz, 1.5H; CHCH3), 1.52 ppm (d, J=7.3 Hz, 1.5H; CHCH3) ;
13C NMR (125 MHz, CDCl3): d=169.8 (d, JC–P=5.4 Hz; C=O), 135.0
(d, JC-P=6.8 Hz; ipso-C-Ph), 134.7 (C-ipso-OCH2Ph), 130.0, 129.8
129.6, 128.7, 128.7, 128.4, 128.3, 126.0 (CH-Ph), 120.6 (d, JC–P=
2.5 Hz; CH-Ph), 120.5 (d, JC–P=2.5 Hz; CH-Ph), 68.1, 67.7 (OCH2Ph),
50.8, 50.5 (CHCH3), 20.5 ppm (d, J=5.6 Hz; CHCH3) ;
31P NMR
(202 MHz, CDCl3): d=7.93 (0.5P), 7.51 ppm (0.5P).
Phenyl-(hexoxy-l-alaninyl)-phosphorochloridate (18b)
Prepared according to standard procedure 1 in 87% yield. 1H NMR
(500 MHz, CDCl3): d=7.24–7.18 (m, 5H; H-Ph), 4.34–4.20 (m, 1H;
NH), 4.20–4.05 (m, 3H; CHCH3 and OCH2), 4.03–3.94 (m, 2H;
OCH2CH2), 1.66–1.56 (m, 4H; OCH2CH2CH2CH2), 1.59–1.53 (m, 3H;
CHCH3), 1.37–1.31 (m, 4H; CH2CH2CH3), 0.94–0.87 ppm (CH2CH3) ;
13C NMR (125 MHz, CDCl3): d=172.8 (d, JC–P=7.8 Hz; C=O), 172.7
(d, JC–P=7.8 Hz; C=O), 149.8 (d, JC–P=8.0 Hz; ipso-C-Ph), 149.8 (d, JC–
P=8.0 Hz; ipso-C-Ph), 129.9, 129.8, 125.9, 125.9 (CH-Ph), 120.6 (d, JC–
P=5.3 Hz; CH-Ph), 66.0 65.9 (OCH2), 50.8, 50.5 (CHCH3), 31.3
(OCH2CH2), 28.4 (OCH2CH2CH2), 25.4 (OCH2CH2CH2CH2), 22.5
(CH2CH3), 22.4 (d, JC–P=5.6 Hz; CHCH3), 22.3 (d, JC–P=5.6 Hz;
CHCH3), 13.9 ppm (CH2CH3) ;
31P NMR (202 MHz, CDCl3): d=7.96
(0.5P), 7.64 ppm (0.5P).
Phenyl-(pentoxy-l-alaninyl)-phosphorochloridate (18c)
Prepared according to standard procedure 1 in 96% yield. 1H NMR
(500 MHz, CDCl3): d=7.46–7.31 (m, 2H; H-Ph), 7.28–7.22 (m, 3H; H-
Ph), 4.68 (br s; NH), 4.18–4.09 (m, 3H; OCH2, CHCH3), 1.73–1.71 (m,
2H; OCH2CH2), 1.68–1.65 (m, 5H; OCH2CH2CH2, CHCH3), 1.36–1.32
(m, 2H; CH2CH3), 0.92–0.89 ppm (m, 3H; CH3) ;
13C NMR (125 MHz,
CDCl3): d=172.7 (d, JC–P=7.7 Hz; C=O), 172.6 (d, JC–P=7.3 Hz; C=O),
149.6 (d, JC–P=8.1 Hz; ipso-C-Ph), 149.4 (d, JC–P=8.0 Hz; ipso-C-Ph),
129.9, 129.8, 125.9, 125.8 (CH-Ph), 120.5 (d, JC–P=5.5 Hz, CH-Ph),
65.9 65.8 (OCH2), 50.5, 50.3 (CHCH3), 31.3 (OCH2CH2), 28.3
(OCH2CH2CH2), 22.4 (CH2CH3), 22.4 (d, J=5.8 Hz, CHCH3), 22.4 (d,
J=5.7 Hz, CHCH3), 13.9 ppm (7CH2CH3) ;
31P NMR (202 MHz, CDCl3):
d=7.92 (0.5P), 7.61 ppm (0.5P).
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1-Naphthyl-(isopropoxy-l-alaninyl)-phosphorochloridate (18d)
Prepared according to standard procedure 1 in 84% yield. 1H NMR
(500 MHz, CDCl3): d=8.10–8.07 (m, 1H; CH-Naph), 7.88–7.82 (m,
1H; CH-Naph), 7.76–7.56 (m, 1H; H-Naph), 7.6–7.3 (m, 4H; H-
Naph), 5.13–5.09 (m, 1H; OCH(CH3)2), 4.54 (br s, 1H; NH), 4.26–4.22
(m, 1H; CHCH3), 1.56 (d, J=7.0 Hz, 1.5H; CHCH3), 1.54 (d, J=
7.0 Hz, 1.5H; CHCH3), 1.34–1.25 ppm (m, 6H; OCH(CH3)2) ;
13C NMR
(125 MHz, CDCl3): d=173.1 (C=O), 149.8 (d, JC–P=8.0 Hz; ipso-C-Ph),
147.3 (ipso-C-Ph), 134.9, 134.8 (C-Naph), 129.0, 127.6, 126.9, 126.7,
126.3 (CH-Naph), 126.1 (d, JC–P=8.3 Hz; C-Naph), 125.5, 124.4,
122.0, 121.5, 121.4, 121.3, 116.2, 116.1, 115.2 (CH-Naph), 70.6, 69.2
(OCH(CH3)2), 51.0, 50.7 (CHCH3), 21.7, 21.5 (CHCH3), 16.1 ppm
(OCH(CH3)2) ;
31P NMR (202 MHz, CDCl3): d=8.35 (0.5P), 8.03 ppm
(0.5P).
1-Naphthyl-(2,2-dimethyl-propoxy-l-alaninyl)-phosphorochlor-
idate (18e)
Prepared according to standard procedure 1 in 91% yield. 1H NMR
(500 MHz, CDCl3): d=8.20–7.30 (m, 7H; H-Naph), 4.48–4.34 (br s,
1H; NH), 4.38–4.20 (m, 1H; CHCH3), 3.90–3.70 (m, 2H; CH2C(CH3)3),
1.58–1.45 (m, 3H; CHCH3), 0.89 (s, 4.5H; C(CH3)3), 0.87 ppm (s,
4.5H; C(CH3)3) ;
13C NMR (125 MHz, CDCl3): d=171.7 (d, JC–P=2.5 Hz;
C=O), 171.6, (d, JC–P=2.5 Hz; C=O), 146.7 (d, JC–P=6.3 Hz; ipso-C-
Naph), 134.7 (C-Naph), 128.9, 129.0, 127.9, 126.9, 126.8, 126.2 (CH-
Naph), 126.1 (d, JC–P=8.7 Hz; C-Naph), 125.9, 121.4, 121.3 (CH-
Naph), 75.2 (CH2C(CH3)3), 75.1 (CH2C(CH3)3), 50.9 (CHCH3), 50.6
(CHCH3), 26.4 (C(CH3)3), 26.3 (C(CH3)3), 20.9 ppm (d, J=4.8 Hz,
CHCH3) ;
31P NMR (202 MHz, CDCl3): d=8.25 (0.5P), 7.95 ppm (0.5P).
1-Naphthyl-(benzoxy-l-alaninyl)-phosphorochloridate (18 f)
Prepared according to standard procedure 1 in 78% yield. 1H NMR
(500 MHz, CDCl3): d=8.12–7.97 (m, 1H; H-Naph), 7.73–7.57 (m, 1H;
H-Naph), 7.65–7.32 (m, 10H; H-Ar), 5.25–5.21 (m, 2H; OCH2Ph),
4.81–4.78 (m, 1H; NH), 4.23–4.20 (m, 1H; CHCH3), 1.59–1.57 ppm
(m, 3H; CHCH3) ;
13C NMR (125 MHz, CDCl3): d=173.9 (d, JC–P=
6.5 Hz; C=O), 173.8 (d, JC–P=6.5 Hz; C=O), 146.8 (d,
2JC–P=6.3 Hz;
ipso-C-Naph), 135.4, 134.8 (C-Naph), 128.6, 128.4, 128.2, 128.1,
126.7, 126.5, 126.3, 126.0 (d, JC–P=8.2 Hz; C-Naph), 125.7, 124.4,
121.5, 115.2, 115.2 (CH-Ph, CH-Naph), 67.1 (OCH2Ph), 50.2 (CHCH3),
50.1 (d, 3JC–P=2.0 Hz; CHCH3), 21.1 (d, J=5.3 Hz; CHCH3), 21.0 ppm
(d, J=5.3 Hz; CHCH3) ;
31P NMR (202 MHz, CDCl3): d=8.19 (0.5P),
7.94 ppm (0.5P).
Phenyl-(isopropoxy-l-alaninyl)-phosphorochloridate (18g)
Prepared according to standard procedure 1 in 93% yield. 1H NMR
(500 MHz, CDCl3): d=7.41–7.36 (m, 2H; H-Ph), 7.31–7.27 (m, 3H; H-
Ph), 5.21–5.01 (m, 1H; OCH(CH3)2), 4.65 (br s, 1H; NH), 4.21–4.06 (m,
1H; CHCH3), 1.51 (d, J=7.0 Hz, 3H; CHCH3), 1.26–1.19 ppm (m, 6H;
OCH(CH3)2) ;
13C NMR (125 MHz, CD3OD): d=172.2 (d, JC–P=8.2 Hz;
C=O), 172.1 (d, JC–P=9.1 Hz; C<C= >O), 149.8 (d, JC–P=8.4 Hz;
ipso-C-Ph), 149.8 (d, JC–P=8.3 Hz; ipso-C-Ph), 129.9 (CH-Ph), 126.0
(CH-Ph), 120.5 (d, JC–P=5.4 Hz; CH-Ph), 69.8, 69.8 (OCH(CH3)2), 50.9,
50.6 (CHCH3), 21.6, 21.5 (OCH(CH3)2), 20.4 (d, JC–P=4.3 Hz; CHCH3),
20.6 ppm (d, JC–P=4.3 Hz; CHCH3) ;
31P NMR (202 MHz, CDCl3): d=
8.08 (0.5P), 7.71 ppm (0.5P).
Standard Procedure 2: Synthesis of 20a–f, 24a and 24g
A solution of tBuMgCl in THF (1.0m, 1.2 mol equiv.) was added at
0 8C to a stirred solution of 17 or 23 (1 mol equiv.) in THF. The reac-
tion mixture was allowed to warm to room temperature and the
appropriate phosphorochloridate (2.0 mol equiv.) dissolved in an-
hydrous THF was added. The reaction mixture was stirred for 16–
18 h and then evaporated under vacuum to give a crude residue
that was purified by column chromatography on silica gel, eluting
with a gradient of CH3OH (0–5%) in CH2Cl2 to afford products
20a–f, 24a and 24g as white solids.
(2S)-Benzyl 2-{[({(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihy-
dropyrimidin-5-yl)-3’-[(tert-butyldimethylsilyl)oxy]tetrahydro-
furan-2’-yl}methoxy)(phenoxy)phosphoryl]amino}propanoate
(20a)
Prepared according to standard procedure 2 from nucleoside 17
(0.048 g, 0.137 mmol), 18a (0.088 g, 0.27 mmol) in anhydrous THF
(2.4 mL) and tBuMgCl in THF (1m, 0.16 mL). After workup, the
crude product was purified by column chromatography on silica
gel using CH2Cl2/CH3OH (95:5) as eluent to provide 20a as a white
solid (22 mg, 25% yield). 1H NMR (500 MHz, CD3OD): d=7.89 (s,
1H; H-6), 7.35–7.32 (m, 7H; H-Ar), 7.22–7.14 (m, 3H; H-Ar), 5.18–
5.00 (m, 3H; H-1’, OCH2Ph), 4.40–4.39 (m, 1H; H-3’), 4.21–4.12 (m,
2H; CH2-5’), 4.05–4.00 (m, 2H; H-4’, CHCH3), 2.33–2.23 (m, 1H;
CH2a-2’), 2.21 (s, 1.2H; COCH3), 2.20 (s, 1.8H; COCH3), 1.81–1.71 (m,
1H; CH2b-2’) 1.37 (d, J=7.1 Hz, 1.2H; CHCH3), 1.36 (d, J=7.2 Hz,
1.2H; CHCH3), 0.92 (s, 9H; C(CH3)3), 0.11 (s, 1.5H; Si(CH3)2), 0.10, (s,
1.5H; Si(CH3)2), 0.09 ppm (s, 3H; Si(CH3)2) ;
31P NMR (202 MHz,
CD3OD): d=3.89 (0.6P), 3.48 ppm (0.4P); MS (ES
+): m/z (%): 701
[M+H]+ (30), 723.30 [M+Na]+ (100).
(2S)-Hexyl 2-{[({(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihydro-
pyrimidin-5-yl)-3-[(tert-butyldimethylsilyl)oxy]tetrahydrofuran-
2-yl}methoxy)(phenoxy)phosphoryl]amino}propanoate (20b)
Prepared according to standard procedure 2 from nucleoside 17
(0.090 g, 0.256 mmol), 18b (0.177 g, 0.512 mmol) in anhydrous THF
(2.4 mL) and tBuMgCl in THF (1m, 0.30 mL). After workup, the
crude was purified by column chromatography on silica gel with
CH2Cl2/CH3OH (95:5) as eluent to provide 20b as a solid (34 mg,
21% yield). 1H NMR (500 MHz, CD3OD): d=7.90 (s, 1H; H-6), 7.36–
7.31 (m, 2H; H-Ph), 7.24–7.15 (m, 3H; H-Ph), 5.11–5.04 (m, 1H; H-
1’), 4.44–4.42 (m, 1H; H-3’), 4.26–4.17 (m, 2H; CH2-5’), 4.10–4.13 (m,
2H; OCH2), 4.04–4.03 (m, 1H; H-4’), 4.00–3.94 (m, 1H; CHCH3),
2.33–2.26 (m, 1H; CH2a-2’), 2.23 (s, 1.5H; COCH3), 2.22 (s, 1.5H;
COCH3), 1.86–1.78 (m, 1H; CH2b-2’), 1.70–1.63 (OCH2CH2), 1.38–1.28
(m, 9H; (CH2)3CH3, CHCH3), 0.93 (s, 4.5H; C(CH3)3), 0.92 (s, 4.5H;
C(CH3)3), 0.92–0.88 (m, 3H; CH2CH3), 0.11 (s, 1.5H; Si(CH3)2), 0.11, (s,
1.5H; Si(CH3)2), 0.10 ppm (s, 3H; Si(CH3)2) ;
31P NMR (202 MHz,
CD3OD): d=3.80 (0.6P), 3.48 ppm (0.4P); MS (ES
+): m/z (%): 695.85
[M+H]+ (30), 717.50 [M+Na]+ (100).
(2S)-Pentyl 2-{[({(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihy-
dropyrimidin-5-yl)-3-[(tert-butyldimethylsilyl)oxy]tetrahydro-
furan-2-yl}methoxy)(phenoxy)phosphoryl]amino}propanoate
(20c)
Prepared according to standard procedure 2 from nucleoside 17
(0.100 g, 0.284 mmol), 18c (0.189 g, 0.568 mmol) in anhydrous THF
(2.6 mL) and tBuMgCl in THF (1m, 0.33 mL). After workup, the
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crude material was purified by column chromatography on silica
gel with CH2Cl2/CH3OH (95:5) as the eluent to provide 20c as
a solid (50 mg, 28% yield). 1H NMR (500 MHz, CD3OD): d=7.88 (s,
1H; H-6), 7.33–7.28 (m, 2H; H-Ph), 7.21–7.12 (m, 3H; H-Ph), 5.14–
5.06 (m, 1H; H-1’), 4.40–4.38 (m, 1H; H-3’), 4.25–4.16 (m, 2H; CH2-
5’), 4.13–4.10 (m, 2H; OCH2), 4.03–4.00 (m, 1H; H-4’), 4.00–3.94 (m,
1H; CHCH3), 2.35–2.28 (m, 1H; CH2a-2’), 2.25 (s, 3H; COCH3), 1.86–
1.75 (m, 1H; CH2b-2’), 1.73–1.70 (m, 2H; OCH2CH2), 1.69–1.65 (m,
5H; OCH2CH2CH2, CHCH3), 1.36–1.32 (m, 2H; CH2CH3), 0.94 (s, 4.5H;
C(CH3)3), 0.92 (s, 4.5H; C(CH3)3), 0.91–0.89 (m, 3H; CH2CH3), 0.11 (s,
1.5H; Si(CH3)2), 0.11, (s, 1.5H; Si(CH3)2), 0.10 ppm (s, 3H; Si(CH3)2) ;
31P NMR (202 MHz, CD3OD): d=3.85 (0.5P), 3.56 ppm (0.5P); MS
(ES+): m/z (%): 681.8 [M+H]+ (30), 703.50 [M+Na]+ (100).
(2S)-Isopropyl 2-{[({(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihy-
dropyrimidin-5-yl)-3’-[(tert-butyldimethylsilyl)oxy]tetrahydro-
furan-2’-yl}methoxy)(naphthalen-1-yloxy)phosphoryl]amino}-
propanoate (20d)
Prepared according to standard procedure 2 from nucleoside 17
(0.180 g, 0.47 mmol), 18d (0.335 g, 0.94 mmol) in anhydrous THF
(2.4 mL) and tBuMgCl in THF (1m, 0.56 mL). After workup, the
crude material was purified by column chromatography on silica
gel with CH2Cl2/CH3OH (95:5) as the eluent to provide 20d as
a solid (40 mg, 12% yield). 1H NMR (500 MHz, CD3OD): d=8.13–
8.10 (m, 1H; H-Naph), 7.85–7.81 (m, 2H; H-Naph, H-6), 7.71–7.67
(m, 1H; H-Naph), 7.56–7.15 (m, 4H; H-Naph), 5.10–4.90 (m, 2H; H-
1’, OCH(CH3)2), 4.25–4.10 (m, 3H; CH2-5’, H-3’), 4.05–3.94 (m, 2H;
CHCH3, H-4’), 2.26–2.15 (m, 1H; CH2a-2’), 2.23 (s, 3H; COCH3), 2.01–
1.98 (m, 1H; CH2b-2’), 1.38–134 (m, 3H; CHCH3), 1.21 (s, 6H;
CH(CH3)2), 0.86 (s, 9H; C(CH3)3), 0.018 (s, 3H; Si(CH3)2), 0.00 ppm (s,
3H; Si(CH3)2) ;
31P NMR (202 MHz, CD3OD): d=4.31 ppm (1P); MS
(ES+): m/z (%): 703.40 [M+H]+ (30), 725.40 [M+Na]+ (100); re-
versed-phase HPLC, eluting with H2O/CH3CN from 90:10 to 0:100
in 30 min, flow=1 mLmin1, l=254 nm, tR=24.85 min.
(2S)-Neopentyl 2-{[({(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-di-
hydropyrimidin-5-yl)-3’-[(tert-butyldimethylsilyl)oxy]tetrahy-
drofuran-2’-yl}methoxy)(naphthalen-1-yloxy)phosphoryl]ami-
no}propanoate (20e)
Prepared according to standard procedure 2 from nucleoside 17
(0.172 g, 0.45 mmol), 18e (0.345 g, 0.9 mmol) in anhydrous THF
(2.3 mL) and tBuMgCl in THF (1m, 0.54 mL). After workup, the
crude material was purified by column chromatography on silica
gel with CH2Cl2/CH3OH (94:6) as the eluent to provide 20e as
a solid (42.0 mg, 13% yield). 1H NMR (500 MHz, CD3OD): d=7.94 (d,
J=8.6 Hz, 0.5H; H-Naph), 7.82 (d, J=8.6 Hz, 0.5H; H-Naph), 7.78–
7.63 (m, 2H; H-Naph, H-6), 7.50–7.21 (m, 5H; H-Naph), 4.98 (dd, J=
10.0, 5.5 Hz, 0.5H; H-1’), 4.90 (dd, J=10.0, 5.5 Hz, 0.5H; H-1’), 4.26–
4.21 (m, 1H; H-3’), 4.12–4.06 (m, 2H; CH2-5’), 3.75–3.71 (m, 1H;
CHCH3), 3.70–3.58 (m, 2H; CH2C(CH3)3), 3.39–3.31 (m, 1H; H-4’),
2.12 (s, 1.5H; COCH3), 2.13–2.08 (m, 1H; CH2a-2’), 2.09 (s, 1.5H;
COCH3), 2.03–1.98 (m, 1H; CH2b-2’), 1.28 (d, J=7.0 Hz, 1.5H;
CHCH3), 1.25 (d, J=7.0 Hz, 1.5H; CHCH3), 0.81 (s, 4.5H; C(CH3)3),
0.79 (s, 4.5H; C(CH3)3), 0.00 (s, 3H; Si(CH3)2), 0.031 (s, 1.5H;
Si(CH3)2), 0.039 ppm (s, 1.5H; Si(CH3)2) ;
31P NMR (202 MHz,
CD3OD): d=4.30 (0.5P), 3.91 ppm (0.5P); MS (ES
+): m/z (%): 731.32
[M+H]+ (30), 753.30 [M+Na]+ (100); reversed-phase HPLC, eluting
with H2O/CH3CN from 90:10 to 0:100 in 30 min, flow=1 mLmin
1,
l=254 nm, tR=17.93 min.
(2S)-Benzyl {[((2’R,3’S,5’R)-5-{2-Acetamido-4-[({[(S)-1-(benzyl-
oxy)-1-oxopropan-2-yl]amino}(naphthalen-1-yloxy)phosphory-
l)oxy]pyrimidin-5-yl}-3’-[(tert-butyldimethylsilyl)oxy]tetrahy-
drofuran-2’-yl)methoxy](naphthalen-1-yloxy)phosphoryl}-l-
alaninate (19 f) and (2S)-Benzyl 2-{[({(2’R,3’S,5’R)-5-(2-Acetami-
do-6-oxo-1,6-dihydropyrimidin-5-yl)-3’-[(tert-butyldimethylsily-
l)oxy]tetrahydrofuran-2’-yl}methoxy)(naphthalen-1-yloxy)-
phosphoryl]amino}propanoate (20 f)
Prepared according to standard procedure 2 from nucleoside 17
(0.095 g, 0.248 mmol), 18 f (0.200 g, 0.495 mmol) in anhydrous THF
(4 mL) and tBuMgCl in THF (1m, 0.37 mL). After workup, the crude
material was purified by column chromatography on silica gel with
CH2Cl2/CH3OH (98:2) as the eluent to provide 19 f as a solid
(56 mg, 21% yield). 1H NMR (500 MHz, CDCl3): d=8.90 (br s, 1H;
NH), 8.88 (br s, 1H; NH), 8.55 (s, 0.3H; H-6), 8.49 (s, 0.3H; H-6), 8.44
(s, 0.4H; H-6), 7.81–7.17 (m, 22H; H-Naph, H-Ph), 5.14–4.94 (m, 5H;
2OCH2Ph, H-1’), 4.47–3.94 (m, 5H; H-3’, CH2-5’, 2CHCH3), 3.78–
3.79 (m, 1H; H-4’), 2.22 (s, 1.5H; COCH3), 2.18 (s, 0.8H; COCH3), 2.22
(s, 0.7H; COCH3), 2.08–2.013 (m, 0.5H; CH2-2’), 1.88–1.86 (m, 0.5H;
CH2-2’), 1.79–1.74 (m, 0.5H; CH2-2’), 1.65–1.59 (m, 0.5H; CH2-2’),
0.90 (s, 2.3H; C(CH3)3), 0.88 (s, 2.3H; C(CH3)3), 0.87 (s, 4.6H; C(CH3)3),
0.07 (s, 1H; Si(CH3)2), 0.05 (s, 1H; Si(CH3)2), 0.15 (s, 1H; Si(CH3)2),
0.00 (s, 2H; Si(CH3)2), 0.02 ppm (s, 1H; Si(CH3)2) ;
31P NMR
(202 MHz, CD3OD): d=3.96 (0.25P), 3.81 (0.25P), 3.25 (0.5P), 3.19
(0.7P), 3.06 ppm (0.3P); MS (ES+): m/z (%): 1120.32 [M+H]+ (60),
1142.30 [M+Na]+ (100).
Further elution of the crude mixture with CH2Cl2/CH3OH (95:5)
yielded 20 f as a solid (98 mg, 59% yield). 1H NMR (500 MHz,
CD3OD): d=8.10 (d, J=8.6 Hz, 1H; H-Naph), 7.87 (d, J=8.6 Hz, 1H;
H-Naph), 7.72–7.62 (m, 2H, H-Naph; H-6), 7.53–7.39 (m, 4H; H-
Naph), 7.32–7.27 (m, 5H; H-Ph), 5.12–5.05 (m, 2H; OCH2Ph), 4.98
(dd, J=10.0, 5.5 Hz, 1H; H-1’), 4.26–4.14 (m, 4H; H-3’, CH2-5’,
CHCH3), 3.97–3.92 (m, 1H; H-4’), 2.22 (s, 3H; COCH3), 2.12–2.06 (m,
1H; CH2a-2’), 1.40–1.06 (m, 4H; CH2b-2’, CHCH3), 0.88 (s, 4.5H;
C(CH3)3), 0.87 (s, 4.5H; C(CH3)3), 0.05 (s, 1.5H; Si(CH3)2), 0.03 (s,
1.5H; Si(CH3)2), 0.02 (s, 1.5H; Si(CH3)2), 0.08 ppm (s, 1.5H;
Si(CH3)2) ;
31P NMR (202 MHz, CD3OD): d=4.09 (0.6P), 3.97 ppm
(0.4P); MS (ES+): m/z (%): 751.85 [M+H]+ (50), 773 [M+Na]+
(100).
Standard Procedure 3: Synthesis of Phosphoramidates 21a–f,
25a and 25g
N-Acetyl-3’-O-silyl-pseudoisocytidine phosphoramidates 20a–f or
3’-O-silyl-pseudoisocytidine phosphoramidates 24a and 24g were
treated with TFA/CH2Cl2 (1:1 v/v) at 0 8C. The resulting reaction mix-
ture was stirred at 0 8C for 6 h. After the reaction was completed
the solvents were evaporated and the residue was purified by
preparative HPLC to afford 21a–f and 25a and 25g, respectively.
(2S)-Benzyl 2-[({[(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihy-
dropyrimidin-5-yl)-3’-hydroxytetrahydrofuran-2’yl]methoxy}-
(phenoxy)phosphoryl)amino]propanoate (21a)
Prepared according to standard procedure 3 from compound 20a
(0.022 g, 0.031 mmol) and TFA/CH2Cl2 (1:1 v/v, 0.3 mL). After
workup, the crude material was purified by preparative HPLC (H2O/
CH3CN from 90:10 to 0:100 in 30 min, flow=20 mLmin
1, l=
280 nm) to yield 21a as a white solid (9.2 mg, 50% yield). 1H NMR
(500 MHz, CD3OD): d=7.88 (s, 1H; H-6), 7.35–7.29 (m, 7H; H-Ar),
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7.21–7.15 (m, 3H; H-Ar), 5.17–5.05 (m, 3H; H-1’, OCH2Ph), 4.31–4.30
(m, 1H; H-3’) 4.25–4.11 (m, 2H; CH2-5’), 4.05–4.00 (m, 2H; H-4’,
CHCH3), 2.36–2.30 (m, 1H; CH2a-2’), 2.21 (s, 1.2H; COCH3), 2.20 (s,
1.8H; COCH3), 1.81–1.75 (m, 1H; CH2b-2’), 1.37 (d, J=7.1 Hz, 1.2H;
CHCH3), 1.35 ppm (d, J=7.2 Hz, 1.2H; CHCH3) ;
13C NMR (125 MHz,
CD3OD): d=175.0 (COCH3), 175.0 (COCH3), 174.9 (d, JC–P=6.13 Hz;
COCH2Ph), 167.6 (C-4), 152.2 (d, JC–P=7.2 Hz; C-ipso-Ph), 152.2 (d,
JC–P=7.09 Hz; C-ipso-Ph), 154.1 (C-6), 152.0 (C-2), 137.2 (C-ipso-
OCH2Ph), 130.8, 129.6, 129.6, 129.4, 129.3, 129.3, 129.2 (CH-Ar),
124.2 (C-5), 124.1 (C-5), 121.5 (d, JC–P=4.5 Hz; CH-Ph), 121.6 (d, JC–
P=4.5 Hz; CH-Ph), 86.3 (d, JC–P=2.3 Hz; C-4’), 86.2 (d, JC–P=2.3 Hz;
C-4’), 75.8 (C-1’), 75.8 (C-1’), 74.0 (C-3’), 73.9 (C-3’), 68.1 (d, JC–P=
5.6 Hz, C-5’), 68.2 (d, JC–P=5.6 Hz, C-5’), 67.9 (OCH2Ph), 67.7
(OCH2Ph), 51.7 (CHCH3), 51.6 (CHCH3), 42.8 (C-2’), 42.0 (C-2’), 23.9
(COCH3), 20.4 (d, JC–P=7.1 Hz; CHCH3), 20.4 ppm (d, JC–P=7.4 Hz;
CHCH3) ;
31P NMR (202 MHz, CD3OD): d=3.94 (0.7P), 3.52 ppm
(0.3P); MS (ES+): m/z (%): 587.18 [M+H]+ (30), 609.53 [M+Na]+
(100); reversed-phase HPLC, eluting with H2O/CH3CN from 90:10 to
0:100 in 30 min, flow=1 mLmin1, l=280 nm, tR=12.79.
(2S)-Hexyl 2-[({[(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihydro-
pyrimidin-5-yl)-3’-hydroxytetrahydrofuran-2’-yl]methoxy}(phe-
noxy)phosphoryl)amino]propanoate (21b)
Prepared according to standard procedure 3 from compound 20b
(0.034 g, 0.049 mmol) and TFA/CH2Cl2 (1:1 v/v, 0.5 mL). After
workup, the crude was purified by preparative HPLC (H2O/CH3CN
from 90:10 to 0:100 in 30 min, flow=20 mLmin1, l=280 nm) to
provide 21b as a solid (17 mg, 60% yield). 1H NMR (500 MHz,
CD3OD): d=7.90 (s, 1H; H-6), 7.37–7.31 (m, 2H; H-Ar), 7.24–7.15
(m, 3H; H-Ar), 5.12 (dd, J=9.8, 5.6 Hz, 0.7H; H-1’), 5.12 (dd, J=9.9,
5.9 Hz, 0.3H; H-1’), 4.34–4.32 (m, 1H; H-3’) 4.29–4.17 (m, 2H; CH2-
5’), 4.13–4.05 (m, 3H, H-4’; OCH2), 4.00–3.93 (m, 1H; CHCH3), 2.37–
2.30 (m, 1H; CH2a-2’), 2.23 (s, 1.2H; COCH3), 2.22 (s, 1.8H; COCH3),
1.84–1.79 (m, 1H; CH2b-2’) 1.65–1.59 (m, 2H; OCH2CH2), 1.40–1.28
(m, 9H; (CH2)3CH3, CHCH3), 0.94–0.86 ppm (m, 3H; CH2CH3) ;
13C NMR (125 MHz, CD3OD): d=175.3 (COCH3), 175.2 (COCH3), 175.0
(CO2-hexyl), 175.0 (CO2-hexyl), 165.5 (C-4), 152.3 (d, JC–P=6.5 Hz; C-
ipso-Ph), 152.2 (d, JC–P=7.5 Hz; C-ipso-Ph), 154.2 (C-6), 152.1 (C-2),
130.8, 126.2, 126.1 (CH-Ph), 124.2 (C-5), 124.2 (C-5), 121.5 (d, JC–P=
4.6 Hz; CH-Ph), 121.5 (d, JC–P=4.7 Hz; CH-Ph), 86.3 (d, JC–P=2.3 Hz;
C-4’), 86.3 (d, JC–P=2.3 Hz; C-4’), 75.9 (C-1’), 75.8 (C-1’), 74.1 (C-3’),
73.9 (C-3’), 68.1 (d, JC–P=5.9 Hz; C-5’), 68.3 (d, JC–P=6.2 Hz; C-5’),
66.5 (OCH2), 66.5 (OCH2), 51.7 (CHCH3), 51.6 (CHCH3), 41.1 (C-2’),
42.0 (C-2’), 32.6, 29.7, 26.6 (CH2), 23.9 (COCH3), 23.6 (CH2CH3), 20.6
(d, JC–P=6.5 Hz; CHCH3), 20.5 (d, JC–P=7.3 Hz; CHCH3), 14.3ppm
(CH2CH3) ;
31P NMR (202 MHz, CD3OD): d=3.88 (0.6P), 3.58 ppm
(0.4P); MS (ES+): m/z (%): 581.23 [M+H]+ (34), 603.57 [M+Na]+
(100); reversed-phase HPLC, eluting with H2O/CH3CN from 90:10 to
0:100 in 30 min, flow=1 mLmin1, l=254 nm, tR=15.11.
(2S)-Pentyl 2-[({[(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihy-
dropyrimidin-5-yl)-3’-hydroxytetrahydrofuran-2’-yl]methoxy}-
(phenoxy)phosphoryl)amino]propanoate (21c)
Prepared according to standard procedure 3 from compound 20c
(0.050 g, 0.078 mmol) and TFA/CH2Cl2 (1:1 v/v, 0.5 mL). After
workup, the crude was purified by preparative HPLC (H2O/CH3CN
from 90:10 to 0:100 in 30 min, flow=20 mLmin1, l=280 nm) to
give 21c as a solid (6.5 mg, 16% yield). 1H NMR (500 MHz, CD3OD):
d=7.90 (s, 0.5H; H-6), 7.85 (s, 0.5H; H-6), 7.38–7.29 (m, 2H; H-Ar),
7.24–7.15 (m, 3H; H-Ar), 5.12 (dd, J=9.8, 5.6 Hz, 0.5H; H-1’), 5.09
(dd, J=9.9, 5.9 Hz, 0.5H; H-1’), 4.35–4.32 (m, 1H; H-3’) 4.30–4.21
(m, 2H; CH2-5’), 4.15–4.05 (m, 3H; H-4’, OCH2), 4.00–3.94 (m, 1H;
CHCH3), 2.37–2.31 (m, 1H; CH2a-2’), 2.23 (s, 1.5H; COCH3), 2.22 (s,
1.5H; COCH3), 1.84–1.72 (m, 1H; CH2b-2’), 1.64–1.61 (m, 2H;
OCH2CH2), 1.40–1.28 (m, 9H; (CH2)3CH3, CHCH3), 0.93–0.91 ppm (m,
3H; CH2CH3) ;
13C NMR (125 MHz, CD3OD): d=176.0 (COCH3), 175.2
(COCH3), 175.0 (CO2-pentyl), 175.0 (CO2-pentyl), 165.5 (C-4), 157.7
(C-6), 152.3 (d, JC–P=6.5 Hz; C-ipso-Ph), 152.2 (d, JC–P=7.5 Hz; C-
ipso-Ph), 152.1 (C-2), 130.6, 126.2, 126.1 (CH-Ph), 124.1 (C-5), 121.5
(d, JC–P=4.6 Hz; CH-Ph), 121.5 (d, JC–P=4.7 Hz; CH-Ph), 86.3 (d, JC–
P=2.3 Hz; C-4’), 75.9 (C-1’), 75.8 (C-1’), 74.1 (C-3’), 74.0 (C-3’), 68.3
(d, JC–P=5.9 Hz; C-5’), 68.1 (d, JC–P=6.2 Hz; C-5’), 66.5 (OCH2), 51.7
(CHCH3), 51.6 (CHCH3), 42.0 (C-2’), 29.4, 29.1 (CH2), 23.9 (COCH3),
23.4 (CH2CH3), 20.6 (d, JC–P=6.5 Hz; CHCH3), 20.5 (d, JC–P=7.3 Hz;
CHCH3), 14.3 ppm (CH2CH3) ;
31P NMR (202 MHz, CD3OD): d=3.92
(0.5P), 3.60 ppm (0.5P); MS (ES+): m/z (%): 567.20 [M+H]+ (34),
589.30 [M+Na]+ (100); reversed-phase HPLC, eluting with H2O/
CH3CN from 90:10 to 0:100 in 30 min, flow=1 mLmin
1, l=
254 nm, tR=17.44.
(2S)-Isopropyl 2-[({[(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihy-
dropyrimidin-5-yl)-3’-hydroxytetrahydrofuran-2’-yl]methoxy}-
(naphthalen-1-yloxy)phosphoryl)amino]propanoate (21d)
Prepared according to standard procedure 3 from compound 20d
(40 mg, 0.057 mmol) and TFA/CH2Cl2 (1:1 v/v, 0.3 mL). After
workup, the crude was purified by preparative HPLC (H2O/MeCN
from 90:10 to 0:100 in 30 min, flow=20 mLmin1, l=280 nm) to
yield 21d as a white solid (12.6 mg, 37% yield). 1H NMR (500 MHz,
CD3OD): d=8.10–7.97 (m, 1H; H-Naph), 7.75–7.65 (m, 2H; H-Naph,
H-6), 7.59–7.47 (m, 1H; H-Naph), 7.41–7.37 (m, 3H; H-Naph), 7.32
(d, J=8.12 Hz, 0.75H; H-Naph), 7.30 (d, J=8.12 Hz, 0.25H; H-Naph),
4.93–4.90 (m, 1H; H-1’), 4.85–4.79 (m, 1H; OCH(CH3)2), 4.17–4.12
(m, 2H; CH2-5’), 4.11–4.08 (m, 1H; H-3’), 3.94–3.87 (m, 2H; CHCH3,
H-4’), 2.16–2.10 (m, 1H; CH2a-2’), 2.12 (s, 3H; COCH3), 2.08–1.99 (m,
1H; CH2b-2’), 1.24 (d, J=7.5 Hz, 3H; CHCH3), 1.09 (d, J=6.4 Hz, 3H;
OCH(CH3)2), 1.08 ppm (d, J=6.5 Hz, 3H, OCH(CH3)2) ;
13C NMR
(125 MHz, CD3OD): d=173.6 (COCH3), 173.4 (C=O), 173.1 (C=O),
166.2 (C-4), 154.2 (C-6), 152.2 (C-2), 146.7 (d, JC–P=8.3 Hz; C-ipso-
Naph), 134.9 (C-Naph), 127.5 (CH-Naph), 126.5 (d, JC–P=5.2 Hz; C-
Naph), 126.0, 126.0, 125.1, 124.6 (CH-Naph), 123.2 (C-5), 121.3 (CH-
Naph), 114.9 (d, JC–P=3.6 Hz; CH-Naph), 85.0 (C-4’), 74.4 (C-1’), 72.6
(C-3’), 68.8 (OCH), 66.9 (d, JC–P=5.02 Hz; C-5’), 50.6 (CHCH3), 40.2 (C-
2’), 22.5 (COCH3), 20.5 (OCH(CH3)2), 20.4 (OCH(CH3)2), 19.1 (d, JC–P=
7.3 Hz; CHCH3), 19.0 ppm (d, JC–P=7.3 Hz; CHCH3) ;
31P NMR
(202 MHz, CD3OD): d=4.34 ppm; MS (ES
+): m/z (%): 611.20 [M+
Na]+ (100); reversed-phase HPLC, eluting with H2O/CH3CN from
90:10 to 0:100 in 30 min, flow=1 mLmin1, l=254 nm, tR=
18.72 min.
(2S)-Neopentyl 2-[({[(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-di-
hydropyrimidin-5-yl)-3’-hydroxytetrahydrofuran-2’-yl]me-
thoxy}(naphthalen-1-yloxy)phosphoryl)amino]propanoate
(21e)
Prepared according to standard procedure 3 from compound 20e
(42 mg, 0.056 mmol) and TFA/CH2Cl2 (1:1 v/v, 0.3 mL). After
workup, the crude was purified by preparative HPLC (H2O/CH3CN
from 90:10 to 0:100 in 30 min, flow=20 mLmin1, l=280 nm) to
give 21e as a solid (16.0 mg, 46% yield). 1H NMR (500 MHz,
CD3OD): d=8.02–7.99 (m, 1H; H-Naph), 7.75–7.70 (m, 1H; H-Naph),
7.66 (s, 1H; H-6), 7.57 (d, J=7.8 Hz, 0.7H; H-Naph), 7.52 (d, J=
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8.4 Hz, 0.3H; H-Naph), 7.40–7.34 (m, 3H; H-Naph), 7.32–7.28 (m,
0.7H; H-Naph), 7.31–7.28 (m, 0.3H; H-Naph), 4.89 (dd, J=10.1,
6.2 Hz, 1H; H-1’), 4.20–4.12 (m, 2H; CH2-5’), 4.13–4.07 (m, 1H; H-3’),
4.00–3.96 (m, 1H; CHCH3), 3.92–3.90 (m, 1H; H-4’), 3.73, 3.66 (AB
system, J=10.5 Hz, 1H; OCH2C(CH3)3), 3.72, 3.62 (AB system, J=
10.5 Hz, 1H; OCH2C(CH3)3), 2.16–2.10 (m, 1H; CH2a-2’), 2.10 (s, 2H;
COCH3), 2.09 (s, 1H; COCH3), 2.16–2.10 (m, 1H; CH2b-2’), 1.26 (d, J=
7.18 Hz, 1.2H; CHCH3), 1.24 (d, J=7.3 Hz, 1.8H; CHCH3), 0.79 (s, 3H;
OCH2C(CH3)3), 0.81 ppm (s, 6H; OCH2C(CH3)3) ;
13C NMR (125 MHz,
CD3OD): d=173.7 (COCH3), 171.2 (COCH2C(CH3)3), 170.9
(COCH2C(CH3)3), 159.2 (C-4), 153.5 (C-6), 152.1 (C-2), 146.7 (d, JC–P=
6.8 Hz; C-ipso-Naph), 134.9 (C-Naph), 127.4 (CH-Naph), 126.5 (d, JC–
P=5.2 Hz, C-Naph), 126.3, 126.1, 125.1, 124.6 (CH-Naph), 123.1 (C-
5), 115.0 (d, JC–P=3.6 Hz; CH-Naph), 85.0 (C-4’), 74.4 (C-1’), 74.4 (C-
1’), 74.4 (OCH2C(CH3)3), 72.6 (C-3’), 66.9 (d, JC–P=5.0 Hz; C-5’), 66.9
(d, JC–P=5.0 Hz; C-5’), 50.5 (CHCH3), 50.5 (CHCH3), 40.8 (C-2’), 30.9
(OCH2C(CH3)3), 25.3 (OCH2C(CH3)3), 22.5 (COCH3), 19.2 ppm (d, JC–P=
7.3 Hz; CHCH3).
31P NMR (202 MHz, CD3OD): d=4.36 (0.7P),
4.09 ppm (0.3P); MS (ES+): m/z (%): 639.21 [M+Na]+ (100); re-
versed-phase HPLC, eluting with H2O/CH3CN from 90:10 to 0:100
in 30 min, flow=1 mLmin1, l=254 nm, tR=11.95 min.
(2S)-Benzyl 2-[({[(2’R,3’S,5’R)-5-(2-Acetamido-6-oxo-1,6-dihy-
dropyrimidin-5-yl)-3’-hydroxytetrahydrofuran-2’-yl]methoxy}-
(naphthalen-1-yloxy)phosphoryl)amino]propanoate (21 f)
Prepared according to standard procedure 3 from the compound
20 f (98 mg, 0.130 mmol) and and TFA/CH2Cl2 (1:1 v/v, 0.3 mL).
After workup, the crude material was purified by preparative HPLC
(H2O/CH3CN from 90:10 to 0:100 in 30 min, flow=20 mLmin
1, l=
280 nm) to give 21 f as a white solid (20.1 mg, 25% yield). 1H NMR
(500 MHz, CD3OD): d=8.13–8.11 (m, 1H; H-Naph), 7.86–7.84 (m,
2H; H-Naph, H-6), 7.71–7.64 (m, 1H; H-Naph), 7.51–7.46 (m, 3H; H-
Naph), 7.32 (d, J=8.12 Hz, 0.65H; H-Naph), 7.30 (d, J=8.12 Hz,
0.35H; H-Naph), 7.33–7.28 (m, 5H; H-Ph), 5.14–5.07 (m, 2H;
OCH2Ph), 5.03 (dd, J=8.6, 5.5 Hz, 1H; H-1’), 4.25–4.20 (m, 3H; CH2-
5’, H-3’), 4.15–4.09 (m, 1H; CHCH3), 4.03–4.00 (m, 1H; H-4’), 2.21 (s,
3H; COCH3), 2.19–2.15 (m, 1H; CH2a-2’), 1.49–1.36 (m, 1H; CH2b-2’),
1.37 (d, J=7.5 Hz, 3H; CHCH3) ;
13C NMR (125 MHz, CD3OD): d=
173.6 (COCH3), 173.6 (C=O), 173.5 (C=O), 166.2 (C-4), 154.2 (C-6),
150.6 (C-2), 146.7 (d, JC–P=8.3 Hz; C-ipso-Naph), 146.6 (d, JC–P=
8.3 Hz; C-ipso-Naph), 135.8, 134.9, 134.8 (C-Naph), 128.2 128.1,
127.9, 127.9, 127.8, 127.4 (CH-Naph), 126.5 (d, JC–P=5.17 Hz; C-
Naph), 126.4, 126.3, 126.1, 125.1 (CH-Naph), 124.6 (C-5), 124.5 (C-5),
121.3, 121.3 (CH-Naph), 115.1 (d, JC–P=3.6 Hz; CH-Naph), 115.0 (d,
JC–P=3.6 Hz; CH-Naph), 85.1 (C-4’), 85.0 (C-4’), 74.3 (C-1’), 74.2 (C-1’),
72.7 (C-3’), 72.6 (C-3’), 69.0 (d, JC–P=5.0 Hz; C-5’), 66.9 (d, JC–P=
5.0 Hz, C-5’), 66.6 (OCH2Ph), 66.6 (OCH2Ph), 50.5 (CHCH3), 50.4
(CHCH3), 40.7 (C-2’), 40.5 (C-2’), 22.5 (COCH3), 19.0 (d, JC–P=7.3 Hz;
CHCH3), 18.9 ppm (d, JC–P=7.3 Hz; CHCH3) ;
31P NMR (202 MHz,
CD3OD): d=4.33 (0.8P), 3.98 ppm (0.2P); MS (ES
+): m/z (%): 659.20
[M+Na]+ (100); reversed-phase HPLC, eluting with H2O/CH3CN
from 90:10 to 0:100 in 30 min, flow=1 mLmin1, l=254 nm, tR=
17.45 min.
2-Amino-5-((2’R,4’S,5’R)-4-[(tert-butyldimethylsilyl)oxy]-5’-
{[(tert-butyldimethylsilyl)oxy]methyl}tetrahydrofuran-2’-yl)pyri-
midin-4(3H)-one (22)
Ammonia (7m) in MeOH (1 mL) was added to a solution of 2-N-
acetyl-2’-deoxy-3’,5’-O-bis(tert-butyldimethylsilyl)pseudoisocytidine
(16, 0.55 g, 1.1 mmol) in CH3OH (5 mL) at 0 8C under an argon at-
mosphere. After 30 min the reaction mixture was allowed to warm
to room temperature and was stirred for 12 h. The volatiles were
removed under vacuum and the crude material was purified by
flash column chromatography using CH2Cl2/CH3OH (95:5) as the
eluent to give 22 as an oil (0.455 g, 90% yield). 1H NMR (500 MHz,
CD3OD): d=7.54 (s, 1H; H-6), 4.94 (dd, J=10.2, 6.0 Hz, 1H; H-1’),
4.31–4.28 (m, 1H; H-3’), 3.74–3. 68 (m, 1H; H-4’), 3.61 (dd, J=11.0,
4.0 Hz, 1H; CH2a-5’), 3.54 (dd, J=11.0, 5.5 Hz, 1H; CH2b-5’), 2.09 (dd,
J=12.5, 6.0 Hz, 1H; CH2a-2’), 1.82–1.76 (m, 1H; CH2b-2’), 0.81 (s, 9H;
SiC(CH3)3), 0.80 (s, 9H; SiC(CH3)3), 0.02 (s, 3H; Si(CH3)2), 0.00 (s, 3H;
Si(CH3)2), 0.01 (s, 3H; Si(CH3)2), 0.02 ppm (s, 3H; Si(CH3)2) ;
13C NMR (125 MHz, CD3OD): d=165.3 (C-4), 155.9 (C-2), 128.7 (C-6),
128.7 (C-6), 116.0 (C-5), 87.5 (C-4’), 74.2 (C-1’), 74.1 (C-3’), 63.4 (C-5’),
41.0 (C-2’), 25.1 (SiC(CH3)3), 25.0 (SiC(CH3)3), 17.8 (SiC(CH3)3), 17.5
(SiC(CH3)3), 5.7 (Si(CH3)2), 5.9 (SiCH3)2), 6.6 (SiCH3)2), 6.6 ppm
(SiCH3)2) ; MS (ES
+): m/z (%): 456.3 [M+H]+ (100); reversed-phase
HPLC, eluting with H2O/CH3CN from 90:10 to 0:100 in 30 min,
flow=1 mLmin1, l=254 nm, tR=19.19 min.
2-Amino-5-{(2’R,4’S,5’R)-4’-[(tert-butyldimethylsilyl)oxy]-5’-(hy-
droxymethyl)tetrahydrofuran-2’-yl}pyrimidin-4(3H)-one (23)
A mixture of TFA and H2O (1:1 v/v, 2.0 mL) was added dropwise to
a solution of 22 (0.244 g, 0.535 mmol) in THF (4 mL) at 0 8C. The re-
action was stirred at room temperature for 2 h under an argon at-
mosphere. The reaction mixture was quenched with NaHCO3 and
concentrated under reduced pressure to afford 23 as glassy solid,
which was used in the next step without further purification
(0.123 g, 67%). 1H NMR (500 MHz, CD3OD): d=7.61 (s, 1H; H-6),
4.92 (dd, J=10.2, 6.0 Hz, 1H; H-1’), 4.35–4.31 (m, 1H; H-3’), 3.82-
3.74 (m, 1H; H-4’), 3.58 (dd, J=11.5, 4.5 Hz, 1H; CH2a-5’), 3.54 (dd,
J=11.5, 4.5 Hz, 1H; CH2b-5’), 2.16–2.10 (m, 1H; CH2a-2’), 1.88–1.82
(m, 1H; CH2b-25’), 0.85 (s, 9H; SiC(CH3)3), 0.06 (s, 3H; Si(CH3)2),
0.01 ppm (s, 3H; Si(CH3)2) ;
13C NMR (125 MHz, CD3OD): d=161.3 (C-
4), 150.3 (C-6), 149.8 (C-2), 123.1 (C-5), 88.5 (C-4’), 85.7 (C-1’), 72.2
(C-3’), 70.0 (C-5’), 37.4 (C-2’), 24.0 (SiC(CH3)3), 19.7 (SiC(CH3)3), 6.1
(Si(CH3)2), 6.4 ppm (Si(CH3)2) ; reversed-phase HPLC, eluting with
H2O/CH3CN from 90:10 to 0:100 in 30 min, flow=1 mLmin
1, l=
254 nm, tR=10.8 min.
(2S)-Benzyl 2-{[({(2’R,3’S,5’R)-5-(2-Amino-6-oxo-1,6-dihydropyr-
imidin-5-yl)-3’-[(tert-butyldimethylsilyl)oxy]tetrahydrofuran-2’-
yl}methoxy)(phenoxy)phosphoryl]amino}propanoate (24a)
Prepared according to standard procedure 2 from nucleoside 23
(0.035 g, 0.1 mmol), 18a (0.071 g, 0.2 mmol) in anhydrous THF
(2 mL) and tBuMgCl in THF (1m, 0.13 mL). After workup, the crude
was purified by column chromatography on silica gel using CH2Cl2/
CH3OH (92:8) as the eluent to give 24a as a solid (0.0223 g, 41%).
1H NMR (500 MHz, CD3OD): d=7.56 (s, 1H; H-6), 7.26–7.19 (m, 7H;
H-Ph), 7.12–7.06 (m, 3H; H-Ph), 5.07–5.01 (m, 2H; OCH2Ph), 4.94
(dd, J=10.0, 6.0 Hz, 1H; H-1’), 4.29–4.21 (m, 1H; H-3’), 4.05–4.01
(m, 2H; CH2-5’), 3.96–388 (m, 1H; CHCH3), 3.86–3.83 (m, 1H; H-4’),
2.10–2.06 (m, 0.3H; H-2’a), 2.04–2.01 (m, 0.7H; H-2’a), 1.74–1.79 (m,
1H; H-2’b), 1.29–1.25 (m, 3H; CHCH3), 0.84 (s, 2.7H; SiC(CH3)3), 0.82
(s, 6.3H; SiC(CH3)3), 0.01 (s, 1.8H; Si(CH3)2), 0.00 ppm (s, 4.2H;
Si(CH3)2) ;
31P NMR (202 MHz, CD3OD): d=3.79 (0.7P), 3.49 ppm
(0.3P).
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(2S)-Isopropyl 2-{[({(2’R,3’S,5’R)-5-(2-Amino-6-oxo-1,6-dihydro-
pyrimidin-5-yl)-3’-[(tert-butyldimethylsilyl)oxy]tetrahydrofur-
an-2’-yl}methoxy)(phenoxy)phosphoryl]amino}propanoate
(24g)
Prepared according to standard procedure 2 from nucleoside 23
(0.035 g, 0.1 mmol), 18g (0.067 g, 0.2 mmol) in anhydrous THF
(1.5 mL) and tBuMgCl in THF (1m, 0.13 mL). After workup, the
crude material was purified by column chromatography on silica
gel using CH2Cl2/CH3OH (92:8) as an eluent to give 24g as a solid
(0.020 g, 32%). 1H NMR (500 MHz, CD3OD): d=7.56 (br s, 1H; H-6),
7.26–7.22 (m, 2H; H-Ph), 7.14–7.07 (m, 3H; H-Ph), 4.94 (dd, J=10.0,
6.0 Hz, 1H; H-1’), 4.87–4.79 (m, 1H; OCH(CH3)2), 4.38–4.31 (m, 1H;
H-3’), 4.12–4.03 (m, 2H; CH2-5’), 3.89–3.88 (m, 1H; H-4’), 3.83–3.77
(m, 1H; CHCH3), 2.13–2.00 (m, 1H; CH2a-2’), 1.79–1.69 (m, 1H; CH2a-
2’), 1.25 (d, J=7.0 Hz, 0.7H; CHCH3), 1.22 (d, J=7.0 Hz, 2.3H;
CHCH3), 1.14 (d, J=6.0 Hz, 3H; OCH(CH3)2), 1.12 (d, J=6.0 Hz, 3H;
OCH(CH3)2), 0.82 (s, 2.3H; SiC(CH3)3), 0.81 (s, 6.7H; SiC(CH3)3), 0.02
(s, 0.7H; Si(CH3)2), 0.05 (s, 0.7H; Si(CH3)2), 0.03 (s, 2.3H; Si(CH3)2),
0.07 ppm (s, 2.3H; Si(CH3)2) ;
31P NMR (202 MHz, CD3OD): d=3.87
(0.3P), 3.57 ppm (0.7P); reversed-phase HPLC, eluting with H2O/
CH3CN from 90:10 to 0:100 in 30 min, flow=1 mLmin
1, l=
254 nm, tR=13.42 min.
(2S)-Benzyl 2-[({[(2’R,3’S,5’R)-5-(2-Amino-6-oxo-1,6-dihydropyr-
imidin-5-yl)-3’-hydroxytetrahydrofuran-2’-yl]methoxy}(phenox-
y)phosphoryl)amino]propanoate (25a)
Trimethylsilyl trifluoromethanesulfonate (14.5 mL, 0.08 mmol) was
added dropwise to a solution of 24a (22.3 mg, 0.034 mmol) in
CH2Cl2 (1.5 mL) at 78 8C. The reaction was stirred for 2 h under an
argon atmosphere. The solvent was removed under reduced pres-
sure and the crude material was purified by preparative HPLC to
yield 25a as a white solid (11.3 mg, 62%). 1H NMR (500 MHz,
CD3OD): d=7.52 (s, 0.9H; H-6), 7.45 (s, 0.1H; H-6), 7.25–7.18 (m,
7H; H-Ph), 7.09–7.05 (m, 3H; H-Ph), 5.05–4.99 (m, 2H; OCH2Ph),
4.91 (dd, J=10.1, 6.1 Hz, 1H; H-1’), 4.22–4.20 (m, 1H; H-3’), 4.13–
4.02 (m, 2H; CH2-5’), 3.97–3.95 (m, 1H; H-4’), 3.91–3.85 (m, 1H;
CHCH3), 2.20 (ddd, J=13.0, 5.5, 2.0 Hz, 1H; CH2-2’a), 1.69 (ddd, J=
13.0, 10.0, 6.0 Hz, 1H; CH2-2’b), 1.28–1.21 ppm (m, 3H; CHCH3) ;
13C NMR (125 MHz, CD3OD): d=170.4 (COCH2Ph), 169.9 (COCH2Ph),
159.7 (C-4), 155.4 (C-6), 152.5 (C-2), 152.1 (d, JC–P=7.1 Hz; C-ipso-
Ph), 137.1 (C-ipso-OCH2Ph), 129.5, 129.4, 128.2, 128.0, 127.9, 127.7,
127.6, 125.6 (CH-Ar), 124.8 (C-5), 120.1 (d, JC–P=4.3 Hz; CH-Ph),
120.1 (d, JC–P=4.5 Hz; CH-Ph), 85.2 (C-4’), 73.7 (C-1’), 72.6 (C-3’),
72.1 (C-3’), 67.0 (OCH2Ph), 66.6 (d, JC–P=5.7 Hz, C-5’), 50.5 (CHCH3),
40.6 (C-2’), 18.9 (d, J=5.9 Hz, CHCH3), 18.9 ppm (d, J=5.87 Hz,
CHCH3) ;
31P NMR (202 MHz, CD3OD): d=3.93 ppm (1P); MS (ES
+):
m/z (%): 545.2 [M+H]+ (100); reversed-phase HPLC, eluting with
H2O/CH3CN from 90:10 to 0:100 in 30 min, flow=1 mLmin
1, l=
254 nm, tR=9.51 min.
(2S)-Isopropyl 2-[({[(2’R,3’S,5’R)-5-(2-Amino-6-oxo-1,6-dihydro-
pyrimidin-5-yl)-3’-hydroxytetrahydrofuran-2’-yl]methoxy}(phe-
noxy)phosphoryl)amino]propanoate (25g)
Prepared according to standard procedure 3 from compound 24g
(10 mg, 0.016 mmol) and TFA/CH2Cl2 (1:1 v/v, 0.6 mL). After
workup, the crude material was purified by preparative HPLC to
give 25g as a solid (4.0 mg, 50%). 1H NMR (500 MHz, CD3OD): d=
7.68 (s, 0.8H; H-6), 7.67 (s, 0.2H; H-6), 7.26–7.20 (m, 2H; H-Ph),
7.15–7.02 (m, 3H; H-Ph), 5.07 (dd, J=10.0, 5.5 Hz, 1H; H-1’), 4.98–
4.96 (m, 1H; OCH(CH3)2), 4.33–4.28 (m, 1H; H-3’), 4.23–4.19 (m, 2H;
CH2-5’), 4.05–4.01 (m, 1H; H-4’), 3.92–3.87 (m, 1H; CHCH3), 2.32–
2.20 (m, 2H; CH2-2’), 1.90–1.80 (m, 2H; CH2-5’), 1.37 (d, J=7.0 Hz,
0.6H; CHCH3), 1.34 (d, J=7.0 Hz, 2.4H; CHCH3), 1.25 (d, J=6.5 Hz,
3H; OCH(CH3)2), 1.23 ppm (d, J=6.5 Hz, 3H; CH(CH3)2) ;
13C NMR
(125 MHz, CD3OD): d=170.2 (COCH(CH3)2), 159.2 (C-4), 153.5 (C-6),
152.1 (C-2), 141.1 (d, JC-P=4.5 Hz; C-ipso-Ph), 129.4, 126.8 (CH-Ph),
123.5 (C-5), 120.2 (d, JC–P=5.7 Hz; CH-Ph), 120.1 (d, JC–P=4.5 Hz;
CH-Ph), 84.8 (d, JC–P=8.4 Hz; C-4’), 84.8 (d, JC–P=8.4 Hz; C-4’), 74.7
(C-1’), 72.8 (C-3’), 68.8 (OCH(CH3)2), 66.8 (d, JC–P=5.7 Hz; C-5’), 50.5
(CHCH3), 40.5 (C-2’), 39.5 (C-2’), 20.6 (OCH(CH3)2), 20.5 (OCH(CH3)2),
19.5 (d, JC–P=7.5 Hz; CHCH3), 19.0 ppm (d, JC–P=7.5 Hz; CHCH3) ;
31P NMR (202 MHz, CD3OD): d=3.91 (0.8P), 3.69 ppm (0.2P); MS
(ES): m/z (%): 495.15 [MH]+ (100); reversed-phase HPLC, eluting
with H2O/CH3CN from 90:10 to 0:100 in 30 min, flow=1 mLmin
1,
l=254 nm, tR=7.75 min.
Carboxypeptidase Y assay
Trizma buffer (300 mL, pH 7.6) was added to compound 21e (5 mg)
dissolved in [D6]acetone (150 mL). The
31P NMR spectrum (202 MHz,
64–128 scans) was recorded at this stage as a reference (blank, t=
0). To this mixture, a stock solution of carboxypeptidase Y (Sigma–
Aldrich, >50 unitsmg1, dissolved in pH7.6 Trizma buffer, to a con-
centration of 50 unitsmL1, EC 3.4.16.1, 130 mL) was added.
31P NMR spectra (128 scans) were recorded with a 3 min delay be-
tween experiments for 14 h at 25 8C.
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Preparation of Phosphoramidate
Prodrugs of 2’-
Deoxypseudoisocytidine
C the difference: 2’-Deoxypseudoisocy-
tidine is a C-nucleoside with antileuke-
mic activity. A series of phosphorami-
date prodrugs of this C-nucleoside were
synthesized. Their synthesis proved
challenging due to unexpected side re-
actions (double phosphorylation and
epimerization). Their enzymatic activa-
tion was found to be similar to that of
N-linked nucleoside ProTides.
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